Mohammad Salem Mohammad

Dr. Mohammad Salem Mohammad

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Pharmacogenomics
Verified
Journal Article
Closed access
MMMohammad Salem Mohammad
Mohammad Salem Mohammad
EDEhab S El Desoky
Ehab S El Desoky
JWJean-Baptiste Woillard
Jean-Baptiste Woillard
RTRomany Helmy Thabet
Romany Helmy Thabet
AAAmany Mohamad Ali
Amany Mohamad Ali
NPNicolas Picard
Nicolas Picard
Aim: We investigated the associations between variants in genes coding for enzymes and transporters related to the 6-mercaptopurine pathway and clinical outcomes in pediatric patients with acute lymphoblastic leukemia. Materials & methods: Statistical association between gender, age and genotypes of selected SNPs, and the risks of hematological toxicity and relapse were investigated using a Cox proportional hazard model in 70 acute lymphoblastic leukemia patients from upper Egypt. Results: We found significant associations between ITPA, IMPDH1, SLC29A1, SLC28A2, SLC28A3 and ABCC4 SNPs and one or more of the hematological toxicity manifestations (neutropenia, agranulocytosis and leukopenia); age was significantly related to relapse. Conclusion: Genetic polymorphisms in enzymes and transporters involved in the 6-mercaptopurine pathway should be considered during its use to avoid hematological toxicity.

19 July 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
MMMohammad Salem Mohammad
Mohammad Salem Mohammad
KTKhaled Mohamed Tawfik
Khaled Mohamed Tawfik

21 July 2021 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
MMMohammad Salem Mohammad
Mohammad Salem Mohammad
WMWaleed Ahmed Mahmoud
Waleed Ahmed Mahmoud
KTKhaled Mohamed Tawfik
Khaled Mohamed Tawfik

6 August 2019 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
MMMohammad Salem Mohammad
Mohammad Salem Mohammad
EAEsraa A. Ahmed
Esraa A. Ahmed
MAMarwa F. Ali
Marwa F. Ali

1 June 2021 in Nephrologie & Therapeutique
Verified
Journal Article
Closed access
MMMohammad Salem Mohammad
Mohammad Salem Mohammad
LALobna A. Abdelzaher
Lobna A. Abdelzaher
DBDalia M. Badary
Dalia M. Badary
SASulaiman Mohammed Alnasser
Sulaiman Mohammed Alnasser
AAAhmed M. Abd-Eldayem
Ahmed M. Abd-Eldayem
The current study investigated the effects of treatment with 300 mg/kg valproic acid on rhabdomyolysis and acute kidney injury induced by intramuscular injection of hypertonic glycerol in rats. Four groups of male wistar rats: control and hypertonic glycerol, valproic acid and valproic acid + hypertonic glycerol treated groups were used. Blood urea nitrogen, serum creatinine, creatinine kinase (CK) and CK MB, myoglobin and renal reduced glutathione (GSH) levels were measured. Histopathological examination of the kidneys was carried out to evaluate the degree of renal injury in each group. The expression of interleukin-1 beta "IL-1β" in renal tissue was detected using immunohistochemistry. Hypertonic glycerol administration led to severe renal tubular damage with a significant elevation of blood urea nitrogen, serum creatinine, creatinine kinase, CK MB and myoglobin levels and overexpression of IL-1β compared to control group. Valproic acid administration attenuated both the muscle injury and the acute kidney injury induced by hypertonic glycerol, estimated through a significant reduction of creatinine kinase, myoglobin, and serum creatinine. Valproic acid administration caused a significant increase in GSH in the hypertonic glycerol + valproic acid group compared to the hypertonic glycerol group. A significant decrease in tubular necrosis grade, and expression of IL-1β in hypertonic glycerol + valproic acid group compared to the hypertonic glycerol group was observed. This study demonstrates, for the first time to the best of our knowledge, that valproic acid could ameliorate the rhabdomyolysis and the related acute kidney injury in rats.

8 November 2021 in Pharmacogenomics
Verified
Journal Article
Closed access
YMYasmine Makarem
Yasmine Makarem
MMMohammad Salem Mohammad
Mohammad Salem Mohammad
MHManal Hassanien
Manal Hassanien
EAEsraa A Ahmed
Esraa A Ahmed
HHHelal F Hetta
Helal F Hetta
AMAlaa Aa Mohamed
Alaa Aa Mohamed
Introduction: Leflunomide is one of the commonly used drugs in treatment of rheumatoid arthritis (RA), which on administration is converted into its active metabolite teriflunomide. Aim: Our aim is...